Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation

Selective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinica...

Full description

Saved in:
Bibliographic Details
Published inCurrent problems in cancer. Case reports Vol. 1; p. 100007
Main Authors Radovic, Billie, Cummings, Caitlyn, Presswala, Lubaina, Rosen, Ronald
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.12.2020
Elsevier
Subjects
Adjuvant hormonal therapy
Breast cancer
Diabetes
Hematology, Oncology, and Palliative Medicine
Hyperglycemic hyperosmolar state
Tamoxifen
Adjuvant hormonal therapy
Breast cancer
Diabetes
Tamoxifen
Hyperglycemic hyperosmolar state
Online AccessGet full text
ISSN2666-6219
2666-6219
DOI10.1016/j.cpccr.2020.100007

Cover

More Information
Summary:Selective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinical case, one patient presented with hyperosmolar hyperglycemic state two months after starting tamoxifen for male breast cancer. Discontinuation of tamoxifen resulted in decreased hemoglobin A1c levels back to baseline and rebound of C- peptide levels.
ISSN:2666-6219
2666-6219
DOI:10.1016/j.cpccr.2020.100007